发明名称 Combinations of Hepatitis C Virus Inhibitors
摘要 The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
申请公布号 US2016158200(A1) 申请公布日期 2016.06.09
申请号 US201314903024 申请日期 2013.07.09
申请人 BRISTOL-MYERS SQUIBB COMPANY 发明人 Hewawasam Piyasena;Lopez Omar D.;Tu Yong;Wang Alan Xiangdong;Xu Ningning;Kadow John F.;Meanwell Nicholas A.;Gupta Samayamunthula Venkata Satya Arun Kumar;Kumar Indasi J. Gopi;Punugupati Suresh Kumar;Belema Makonen
分类号 A61K31/4178;A61K31/444;A61K31/4439;A61K31/497;A61K31/695;A61K31/4545;A61K31/5377;A61K31/437;A61K31/5365;A61K31/519;A61K45/06;A61K31/4725 主分类号 A61K31/4178
代理机构 代理人
主权项 1. A combination comprising an NS5A-targeting compound and an NS5A synergist, which, when administered, provides synergistic anti-HCV activity against variants that contain mutation(s) conferring resistance to the NS5A-targeting compound alone, wherein the NS5A synergist is selected from:RRRRRRRRRRRRRRRRRRRRRRRRR1R2H;RRRRRRRRRRor a pharmaceutically acceptable salt thereof.
地址 Princeton NJ US